Access Statistics for Nancy Devlin

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
"New Age" Decision Making in HTA: Is It Applicable in Asia? 0 0 1 14 0 0 4 59
A Comparison of Alternative Variants of the Lead and Lag Time TTO 0 0 0 0 1 1 5 19
A New Valuation Method: Directly Eliciting Personal Utility Functions 0 0 0 20 1 3 9 71
A Review of NICE Methods Across Health Technology Assessment Programmes: Differences, Justifications and Implications 0 0 0 2 1 2 7 27
A Study of the Relationship Between Health and Subjective Well-being in Parkinson's Disease Patients 1 1 1 2 1 1 2 26
A Study of the Relationship Between Health and Subjective Well-being in Parkinson’s Disease Patients 0 0 0 1 1 3 5 23
A note on the nature of utility in time and health and implications for cost utility analysis 0 0 0 4 0 0 1 34
A theoretical framework for TTO valuations and a taxonomy of TTO approaches: results from a pilot study 0 0 0 6 1 2 5 39
A uniform Time Trade Off method for states better and worse than dead: feasibility study of the ‘lead time’ approach 0 1 2 13 1 3 8 79
Age and Utilities: Issues for HTA 0 0 1 10 1 3 5 50
Allocating Vote: Health — ‘Needs Assessment’ and an Economics-Based Approach 0 0 0 39 0 0 0 131
An Analysis of NICE Technology Appraisal Decisions 'Recommended in Line with Clinical Practice' 0 0 1 11 0 0 7 65
An Investigation of the Feasibility and Cultural Appropriateness of Stated Preference Methods to Generate EQ-5D-5L Values in the United Arab Emirates 0 0 0 1 0 0 5 19
Analysing Hospital Variation in Health Outcome at the Level of EQ-5D Dimensions 0 0 1 33 0 0 2 175
Anchoring Latent Scale Values for the EQ-5D-Y at 0 = Dead 0 0 1 62 0 1 10 44
Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders' Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) 0 0 0 1 3 4 8 60
Assessing the Performance of the EQ-VAS in the NHS PROMs Programme 0 0 0 2 0 0 0 7
Can We Really Compare and Aggregate PRO Data Between People and Settings? Implications for Multi-Country Clinical Trials and HTA 0 1 1 2 0 1 3 26
Comparing the UK EQ-5D-3L and the English EQ-5D-5L Value Sets 0 0 0 8 0 1 3 25
Do Respondents Completing Abstract, Hypothetical Priority-setting Exercises Agree With the Policy Implications of Their Choices? 0 0 0 1 0 1 6 36
Does NICE have a cost effectiveness threshold and what other factors influence its decisions? A discrete choice analysis 0 0 0 12 2 2 3 63
Does the value of quality of life depend on duration? 0 0 0 1 2 2 4 45
Exploring Variations in the Opportunity Cost Cost-effectiveness Threshold by Clinical Area: Results from a Feasibility Study in England 1 2 3 58 8 10 27 124
Is the Aim of the Health Care System to Maximise QALYs? An Investigation of 0 0 0 5 0 0 1 28
Is there a case for using Visual Analogue Scale valuations in Cost-Utility Analysis? 0 0 1 11 1 2 7 97
Methods for the estimation of the NICE cost effectiveness threshold 0 1 2 163 1 4 23 697
New Methods for Analysing the Distribution of EQ-5D Observations 0 0 0 17 0 0 1 29
New Methods for Modelling EQ-5D-5L Value Sets: An Application to English Data 0 0 0 2 1 1 4 17
Operationalising Value Based Pricing of Medicines: A Taxonomy of Approaches 0 0 0 1 0 0 4 8
Opportunity Costs of Implementing NICE Decisions in NHS Wales 0 0 1 4 8 9 15 24
Public Preferences for Health Gains and Cures: A Discrete Choice Experiment 0 0 1 28 2 4 9 40
Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology 0 0 1 20 0 1 3 44
Searching for Cost-effectiveness Thresholds in NHS Scotland 1 1 1 5 9 10 22 45
Shaping the Research Agenda to Estimate Cost-effectiveness Thresholds for Decision Making 0 0 0 4 2 3 6 25
Statistical analysis of EQ-5D profiles: does the use of value sets bias inference? 0 0 0 11 4 4 5 53
The Distribution of the EQ-5D-5L Index in Patient Populations 0 0 0 10 2 3 5 43
The Evolution of HTA in Emerging Markets Health Care Systems: Analysis to Support a Policy Response 0 1 7 22 0 1 15 51
The Influence of Cost-effectiveness and Other Factors on NICE Decisions 0 0 0 0 1 4 8 21
The health state preferences and logistical inconsistencies of New Zealanders: a tale of two tariffs 0 0 3 42 2 5 14 148
The impact of government targets on waiting times for elective surgery: new insights from time-to-event analysis 0 0 0 5 1 1 3 34
The influence of cost-effectiveness and other factors on NICE decisions 0 0 0 50 1 4 14 230
Time Trends in NICE HTA Decisions 0 0 1 2 0 1 4 21
Time to tweak the TTO. But how? 0 0 0 3 1 2 7 49
Truly inefficient or providing better quality of care? Analysing the relationship between riskadjusted hospital costs and patients’ health outcomes 1 1 2 43 1 2 6 156
Understanding Social Preferences Regarding the Prioritisation of Treatments Addressing Unmet Need and Severity 0 0 0 0 2 2 2 4
Understanding individuals’ decisions about vaccination: a comparison between Expected Utility and Regret Theory models 0 0 9 27 1 3 30 82
Using the EQ-5D as a performance measurement tool in the NHS 0 2 6 27 1 3 12 92
Valuing EQ-5D-Y Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ? 0 1 11 46 0 5 32 77
Valuing Health-Related Quality of Life: An EQ-5D-5L Value Set for England 0 0 0 5 2 3 10 71
What Determines the Shape of an EQ-5D Index Distribution? 0 0 0 0 0 0 2 23
What is the Normative Basis for Selecting the Measure of 'Average' Preferences for Use in Social Choices? 0 0 1 15 2 3 8 50
Total Working Papers 4 12 59 871 68 120 401 3,506


Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
"Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making 0 0 0 36 0 1 4 115
3L, 5L, What the L? A NICE Conundrum 0 0 0 1 1 1 2 38
A COMPARISON OF ALTERNATIVE VARIANTS OF THE LEAD AND LAG TIME TTO 0 0 0 0 2 3 4 47
A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE) 0 0 0 1 0 1 2 9
A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact? 0 0 2 6 1 2 8 41
A new method for valuing health: directly eliciting personal utility functions 0 0 1 2 0 0 4 19
A new tool for creating personal and social EQ-5D-5L value sets, including valuing ‘dead’ 0 0 0 0 2 2 4 5
A note on the nature of utility in time and health and implications for cost utility analysis 0 0 2 7 2 2 5 49
A theoretical framework for TTO valuations of health 0 0 0 31 0 0 2 130
A uniform time trade off method for states better and worse than dead: feasibility study of the ‘lead time’ approach 0 0 0 32 1 1 1 82
A ‘new and improved’ EQ-5D valuation questionnaire? 0 0 0 0 0 0 3 21
All Male Panels and Other Diversity Considerations for ISPOR 0 0 0 0 0 0 0 2
An Analysis of NICE’s ‘Restricted’ (or ‘Optimized’) Decisions 0 0 0 8 0 0 2 71
An exploration of methods for obtaining 0 = dead anchors for latent scale EQ-5D-Y values 0 0 6 6 0 2 37 37
Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) 0 1 2 2 0 1 3 35
Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial 0 0 0 1 1 4 4 20
Comment: Financing New Zealand’s Tertiary Education: How Much Subsidy? 0 0 0 2 0 0 1 5
Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets 0 0 0 0 1 1 6 13
Continuity through change: The rhetoric and reality of health reform in New Zealand 0 0 0 10 0 0 2 43
Correction to: 3L, 5L, What the L? A NICE Conundrum 0 0 0 0 0 0 1 32
Correction to: Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets 0 0 0 0 0 1 5 13
Do people with private health insurance attach a higher value to health than those without insurance? Results from an EQ-5D-5 L valuation study in Ireland 0 0 0 0 2 2 6 6
Does NICE have a cost‐effectiveness threshold and what other factors influence its decisions? A binary choice analysis 0 0 2 134 0 1 9 483
EQ-5D and the EuroQol Group: Past, Present and Future 0 0 1 1 1 4 14 32
Getting Health Economics into Practice, Edited by David Kernick. Radcliffe Medical Press, Oxford, 2002. No. of pages: 358. ISBN 1‐85775‐575‐8 1 1 9 27 2 3 21 105
Head-to-head comparison of health-state values derived by a probabilistic choice model and scores on a visual analogue scale 0 0 0 1 1 1 2 13
Health care spending and economic output: Granger causality 0 1 2 232 2 4 8 617
INTER‐PROVIDER COMPARISON OF PATIENT‐REPORTED OUTCOMES: DEVELOPING AN ADJUSTMENT TO ACCOUNT FOR DIFFERENCES IN PATIENT CASE MIX 0 0 0 0 0 0 1 10
Identifying the impact of government targets on waiting times in the NHS 1 2 4 94 1 3 6 218
Impact of mapped EQ-5D utilities on cost-effectiveness analysis: in the case of dialysis treatments 0 0 0 0 0 0 6 18
International Valuation Protocol for the EQ-5D-Y-3L 0 0 0 1 0 2 18 27
Is there a case for using visual analogue scale valuations in cost‐utility analysis? 0 0 0 38 2 2 3 288
Lead versus lag-time trade-off variants: does it make any difference? 0 0 0 0 1 1 2 30
Local health care expenditure plans and their opportunity costs 0 0 1 5 0 0 3 23
Logical inconsistencies in survey respondents' health state valuations ‐ a methodological challenge for estimating social tariffs 0 0 2 13 0 0 5 97
New methods for modelling EQ‐5D‐5L value sets: An application to English data 0 0 0 0 1 1 10 20
One-to-one versus group setting for conducting computer-assisted TTO studies: findings from pilot studies in England and the Netherlands 0 0 0 1 0 0 1 20
Operationalizing Value-Based Pricing of Medicines 0 0 0 8 0 0 4 46
Patient‐reported outcome measures in the NHS: new methods for analysing and reporting EQ‐5D data 0 0 1 21 0 1 6 68
Review of Valuation Methods of Preference-Based Measures of Health for Economic Evaluation in Child and Adolescent Populations: Where are We Now and Where are We Going? 0 3 6 6 2 7 13 17
Searching for cost effectiveness thresholds in the NHS 0 0 0 19 0 1 10 157
TRULY INEFFICIENT OR PROVIDING BETTER QUALITY OF CARE? ANALYSING THE RELATIONSHIP BETWEEN RISK‐ADJUSTED HOSPITAL COSTS AND PATIENTS' HEALTH OUTCOMES 0 0 0 0 1 3 5 70
The Influence of Cost‐Effectiveness and Other Factors on Nice Decisions 0 0 0 1 1 1 2 38
The Purchasing of Health Care by Primary Care Organisations. An evaluation and Guide to Future Policy, by N. Mays, S. Wyke, G. Malbon, N. Goodwin. Open University Press, Buckingham and Philadelphia, 2001. No. of pages: 320. ISBN 0‐335‐20900‐9 0 0 0 13 1 1 2 78
The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule 0 0 1 6 0 0 4 78
The cost-effectiveness of mammography screening: evidence from a microsimulation model for New Zealand 0 0 0 22 0 0 1 68
The development of new research methods for the valuation of EQ-5D-5L 0 0 0 0 0 0 0 19
The effects of denturism: New Zealand dentists' response to competition 0 0 0 0 0 0 3 5
The effects of lead time and visual aids in TTO valuation: a study of the EQ-VT framework 0 0 0 2 0 0 1 18
The impact of price transparency on consumers and providers: A scoping review 0 1 2 2 2 7 13 14
Time to tweak the TTO: results from a comparison of alternative specifications of the TTO 0 0 0 2 0 0 0 43
Utility Values for Health States in Ireland: A Value Set for the EQ-5D-5L 0 0 1 1 0 0 6 22
Valuing EQ-5D-5L health states ‘in context’ using a discrete choice experiment 0 0 0 1 2 2 3 18
Valuing health‐related quality of life: An EQ‐5D‐5L value set for England 0 0 0 9 0 1 12 65
‘Is there a case for using visual analogue scale valuations in CUA? Yes there is a case, but what does it add to ordinal data?’ a rejoinder 0 0 0 8 0 0 2 54
Total Journal Articles 2 9 45 813 33 70 302 3,712


Book File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
Cost-Effectiveness Thresholds: Economic and ethical issues 0 2 37 105 9 25 152 421
Getting the Most out of PROMs: Putting Health Outcomes at the Heart of NHS Decision-Making 2 3 4 9 4 10 20 66
How Much Should We Spend on the NHS? 0 0 0 1 1 1 4 9
Incorporating Multiple Criteria in HTA: Methods and Processes 1 2 5 10 3 5 12 29
Total Books 3 7 46 125 17 41 188 525


Statistics updated 2021-09-05